Multi-Strain Probiotic Formulation for Treatment-Resistant OCD

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for obsessive-compulsive disorder (OCD) are inadequate for a significant portion of patients, and the underlying pathophysiology remains unclear, with existing therapies showing limited efficacy and high rates of treatment resistance.

Innovation Solution

A multi-strain probiotic formulation comprising Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium infantis, along with glutamine, is administered to modulate the gut microbiome, producing GABA and addressing neurotransmitter imbalances to alleviate OCD symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard serotonergic antidepressants are used to treat OCD, then some patients show improvement, but a significant portion of patients do not respond effectively

Engineering Contradiction:

ImproveTreatment effectivenessVSAvoidResponse variability among patients

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from serotonergic antidepressants to a multi-strain probiotic formulation containing Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium infantis. This parameter change targets the gut microbiota-gut-brain axis, offering an alternative mechanism that may respond differently across patient populations, thereby addressing the variability in treatment response.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces the gut microbiota as an intermediary system between the environment and the brain. The probiotic formulation modulates the gut microbiome, which then influences brain function and behavior through the gut-brain axis. This intermediary approach provides a novel therapeutic pathway that bypasses the limitations of direct central nervous system targeting with antidepressants.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If a multi-strain probiotic formulation is administered for at least six weeks, then OCD symptoms are effectively reduced, but treatment duration increases

Engineering Contradiction:

ImproveSymptom reduction effectivenessVSAvoidTreatment duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent specifies a minimum treatment duration of six weeks, which allows the probiotic formulation to sufficiently modulate the gut microbiota and produce therapeutic effects. This preliminary action period ensures that the treatment has enough time to affect neurotransmitter production and gut-brain axis communication, thereby achieving reliable symptom reduction.

Inventive Principle:

Principle #10Preliminary action

3Object-generated harmful factors

If the probiotic formulation produces GABA, then repetitive behaviors are reduced, but the complexity of the formulation increases

Engineering Contradiction:

ImproveRepetitive behaviorsVSAvoidFormulation complexity

Core Design Contradiction:

Object-generated harmful factorsVSDevice complexity

Solution Approach 1:

The patent combines multiple probiotic strains (Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium infantis) into a single multi-strain formulation. This merging approach leverages the synergistic effects of different strains to enhance GABA production and repetitive behavior reduction, while packaging them as one unified treatment product.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent creates a composite probiotic formulation that integrates multiple bacterial strains with complementary functions. The formulation includes GABA-producing strains alongside other beneficial strains that modulate the gut microbiome. This composite approach maximizes therapeutic effectiveness by combining the benefits of multiple organisms in a single administered product.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The probiotic formulation effectively reduces repetitive behaviors, anxiety-like symptoms, and inflammatory markers, and restores gut integrity, providing an alternative therapeutic approach for OCD, particularly in treatment-resistant cases.

Implementation Method 1

A multi-strain probiotic formulation comprising Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium infantis, along with Glutamine, administered for at least six weeks to modulate the gut microbiota and produce GABA, which helps in reducing OCD symptoms.

Methodology Applied

Scientific EffectGABA production:

Data Source

PatentUS12629398B2Method of alleviating obsessive compulsive disorder symptoms by use of a multi-strain probiotic formulation

Publication Date: 2026.05.19 UNIQUE BIOTECH

AI summary

A method of treating, preventing or ameliorating at least one symptom of obsessive compulsive disorder (OCD) in a subject is disclosed. The method comprises a step in which a multistrain probiotic formulation is administered to the subject. The multistrain probiotic formulation includes the bacterial strains Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve and Bifidobacterium infantis and Glutamine in a concentration range of 100-500 mg.